|
Harrison's Principles of Internal Medicine, 18e
| Part 8. Infectious Diseases > Section 8. Mycobacterial Diseases > |
Chapter 168. Antimycobacterial Agents
Sections: Antimycobacterial Agents: Introduction, Tuberculosis, Nontuberculous Mycobacteria, Conclusion, Further Readings.
Topics Discussed: antimycobacterial agents; therapy of microbial diseases; bacterial, viral, fungal, and protozoal infections.
Excerpt:"Agents used for the treatment of mycobacterial infections, including tuberculosis (TB), leprosy (Hansen's disease), and infections due to nontuberculous mycobacteria (NTM), are administered in multiple-drug regimens for prolonged courses. Currently, more than 150 species of mycobacteria have been identified, the majority of which do not cause disease in humans. While the incidence of disease caused by M. tuberculosis has been declining in the United States, TB remains a leading cause of morbidity and mortality in developing countries—particularly in sub-Saharan Africa, where the HIVepidemic rages. Not only effective drug regimens are needed; without a well-organized infrastructure for diagnosis and treatment of TB, therapeutic and control efforts are severely hampered. Infections with NTM have gained in clinical prominence in the United States and other developed countries. These largely environmental organisms often establish infection in immunocompromised patients or in persons with structural lung disease...."
The content above is only an excerpt.
For full access, log into an existing user account below,
purchase an annual subscription, or
purchase a short-term subscription to the complete website.
|
|
|
|
Or
|
|
|
|